



(51) International Patent Classification:

A61K 31/519 (2006.01) A61K 45/06 (2006.01)  
A61P 35/04 (2006.01)

(21) International Application Number:

PCT/US2025/016654

(22) International Filing Date:

20 February 2025 (20.02.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/556,346 21 February 2024 (21.02.2024) US

(71) Applicant: **FRONTIER MEDICINES CORPORATION** [US/US]; 151 Oyster Point Blvd., 2nd Floor, South San Francisco, CA 94080 (US).

(72) Inventors: **WANG, Yan**; c/o Frontier Medicines Corporation, 151 Oyster Point Blvd., 2nd Floor, South San Francisco, CA 94080 (US). **WEBSTER, Kevin**; c/o Frontier Medicines Corporation, 151 Oyster Point Blvd., 2nd Floor, South San Francisco, CA 94080 (US).

(74) Agent: **DO, Keunbong** et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, CA 94105 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PYRIDOPYRIMIDINE DERIVATIVE AS KRAS G12C INHIBITOR FOR THE TREATMENT OF BRAIN METASTASIS




FIG. 2

(57) Abstract: The present disclosure relates generally to methods for treating or preventing central nervous system (CNS) metastases with a KRAS inhibitor, and more specifically to treating CNS metastases with a pyridopyrimidine derivative.